At OccuRx we are dedicated to identifying and validating novel targets that treat and prevent fibrosis that lead to disease progression and end organ failure. The company’s most advanced molecule drug candidate, OCX063, is being developed as a first-in-class oral therapy for the treatment for both kidney and ocular diseases. OCX063, is a small molecule drug with the potential to prevent the growth of new and abnormal blood vessels and reduce inflammation.
OccuRx was established in 2014 with venture funding from Brandon BioCatalyst (formerly the Medical Research Commercialisation Fund/MRCF), Brandon Capital Partners and Uniseed.
www.occurx.com
OccuRx was established in 2014 with venture funding from Brandon BioCatalyst (formerly the Medical Research Commercialisation Fund/MRCF), Brandon Capital Partners and Uniseed.
www.occurx.com
Employees: 11-50
Founded date: 2014
Investors 2
| Date | Name | Website |
| - | Brandon Ca... | brandoncap... |
| - | Stoic VC | stoicvc.co... |
Mentions in press and media 4
| Date | Title | Description |
| 19.12.2024 | Certa Therapeutics Expands GPR68 Platform through Acquisition of OccuRx | Strengthened Pipeline Targets Multiple Fibrotic Diseases Melbourne, Australia 19 December 2024: Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with fibrotic diseases, today announc... |
| 09.09.2022 | Biotech startup OccuRx raises $16 million for kidney disease trial | Biotech startup OccuRx has raised $16 million to fund clinical phase studies for its oral therapy to treat chronic kidney disease (CKD), a leading cause of death. The round was jointly led by Brandon BioCatalyst and Uniseed and also include... |
| 19.05.2015 | OccuRx Receives up to AU$6.5M in Venture Capital | OccuRx, a Melbourne, Victoria, Australia-based biopharmaceutical company, was launched today with up to AU$6.5M in staged tranches of venture capital funding. A consortium including the Medical Research Commercialisation Fund (MRCF), Brando... |
| - | OccuRx | “OccuRx” |